SCHEMBL4189477

SCHEMBL4189477

O=C(OCc1ccccc1)N1CC(OC(c2ccc(Cl)cc2)c2ccc(Cl)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 10/20 0.51
CNR1 P21554 2/20 0.51
CNR2 P34972 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MEN1 O00255 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
MAPT P10636 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
THPO P40225 1/20 0.45
KMT2A Q03164 1/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4182479 0.81 FAAH (0.48) FAAHCNR1CNR2SMN1; SMN2MEN1
SCHEMBL4186710 0.81 SMN1; SMN2 (0.54) FAAHCNR1CNR2SMN1; SMN2NPC1
SCHEMBL4191420 0.81 FAAH (0.49) FAAHCNR1CNR2DRD3
SCHEMBL23141265 0.80 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AMEN1CYP2D6
SCHEMBL11405129 0.78 TSHR (0.55) FAAHSMN1; SMN2MEN1CYP1A2CYP3A4
SCHEMBL4084892 0.78 FAAH (0.52) FAAHCNR1CNR2SMN1; SMN2NPC1
SCHEMBL28456999 0.77 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL4189458 0.76 DRD3 (0.54) FAAHCNR1CNR2MEN1TP53
SCHEMBL4186767 0.76 MAPT (0.50) FAAHSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL17087416 0.75 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181939-A1 Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders VERNALIS RESEARCH LIMITED. (GB) 2009-07-16 US disclosed
US-20070173486-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs VERNALIS RESEARCH LIMITED (GB) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181939-A1 Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders CNR1, CNR2, GPR119 FAAH 116/4885CNR1 1/4885CNR2 2/4885
US-20070173486-A1 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs CNR1, CNR2, GPR119 FAAH 216/4885CNR1 1/4885CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.